Adamantinoma

Summary

Adamantinoma (MONDO:0002422) is a disease. A subtype of bone carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 3

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Lifetime Prevalence	1-9 / 1 000 000	0.11	Worldwide	Validated
Annual incidence	<1 / 1 000 000	0.01	Europe	Validated

Signs & symptoms

Clinical features (HPO)

3 HPO clinical features (Orphanet curated; top 3 by frequency):

HPO ID	Term	Frequency
HP:0002653	Bone pain	Frequent (30-79%)
HP:0002756	Pathologic fracture	Occasional (5-29%)
HP:0003072	Hypercalcemia	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	adamantinoma
Mondo ID	MONDO:0002422
MeSH	C562741, D050398
OMIM	102660
Orphanet	55881
DOID	DOID:2775, DOID:2776
ICD-11	2013322169
NCIT	C7644
SNOMED CT	307609003
UMLS	C0334556
MedGen	83163
GARD	0016660
Anatomy (UBERON)	UBERON:0002495
Is cancer (heuristic)	no

Also known as: adamantinoma · adamantinoma of long bones · adamantinoma of long bones (morphologic abnormality) · adamantinoma, malignant · Extragnathic adamantinoma · long bone adamantinoma

Disease family

This is a subtype of bone carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone carcinoma › adamantinoma

Related subtypes (6): paranasal sinus carcinoma, bone squamous cell carcinoma, growth hormone-producing pituitary gland carcinoma, osteosarcoma arising in bone Paget disease, pituitary adenocarcinoma, metastatic carcinoma in the bone

Subtypes (1): tibial adamantinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.